Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
| Autor: | Ulf Andreasson, Håkan Widner, Radu Constantinescu, Björn Holmberg, Henrik Zetterberg, Christer Nilsson, Frederick Bostrom, Yulia Surova, Katarina Nägga, Eugeen Vanmechelen, Elisabet Londos, Sara Hall, Kaj Blennow, Hilde Decraemer, Lennart Minthon, Annika Öhrfelt, Oskar Hansson |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Pathology Neurology Amyloid Tau protein Enzyme-Linked Immunosorbent Assay tau Proteins Neuropsychological Tests Severity of Illness Index Statistics Nonparametric Progressive supranuclear palsy Diagnosis Differential Hemoglobins Cerebrospinal fluid Arts and Humanities (miscellaneous) mental disorders medicine Dementia Humans Aged Aged 80 and over Psychiatric Status Rating Scales Amyloid beta-Peptides biology Area under the curve Neurodegenerative Diseases Parkinson Disease Middle Aged Multiple System Atrophy medicine.disease nervous system diseases Cross-Sectional Studies nervous system Synuclein biology.protein alpha-Synuclein Female Neurology (clinical) Supranuclear Palsy Progressive Psychology Biomarkers |
| Zdroj: | Archives of neurology. 69(11) |
| ISSN: | 1538-3687 |
| Popis: | To assess the ability of 5 cerebrospinal fluid(CSF) biomarkers to differentiate between common dementia and parkinsonian disorders.A cross-sectional, clinic-based study.Cerebrospinal fluid samples (N=453) were obtained from healthy individuals serving as controls and from patients with Parkinson disease (PD), PD with dementia(PDD), dementia with Lewy bodies (DLB), Alzheimer disease (AD), progressive supranuclear palsy(PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD).Neurology and memory disorder clinics.Cerebrospinal fluid biomarker levels in relation to clinical diagnosis.Cerebrospinal fluid levels of -synuclein were decreased in patients with PD, PDD, DLB, and MSA but increased in patients with AD. Cerebrospinal fluid levels of α-amyloid 1-42 were decreased in DLB and even further decreased in AD. Cerebrospinal fluid levels of total tau and hyperphosphorylated tau were increased in AD. Multivariate analysis revealed that these biomarkers could differentiate AD from DLB and PDD with an area under the curve of 0.90, with -synuclein and total tau contributing most to the model. Cerebrospinal fluid levels of neurofilament light chain were substantially increased in atypical parkinsonian disorders (ie, PSP, MSA,and CBD), and multivariate analysis revealed that the level of neurofilament light chain alone could differentiate PD from atypical parkinsonian disorders, with an area under the curve of 0.93.Ascertainment of the -synuclein level in CSF somewhat improves the differential diagnosis of AD vs DLB and PDD when combined with established AD biomarkers.The level of neurofilament light chain alone may differentiate PD from atypical parkinsonian disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|